FDA Approves First Second-Generation HIV Drug for Newborns Weighing 2kg

People often assume that because HIV is highly manageable in adults, babies born with the virus automatically have access to the same streamlined, highly effective options. The reality is much starker: until this week, the smallest newborns were excluded from modern, second-generation drugs, leaving them reliant on older, more toxic regimens during their most vulnerable weeks of life.[7]

The U.S. Food and Drug Administration has just changed that baseline. On August 26, the agency approved ViiV Healthcare's Tivicay PD (dolutegravir) for infants weighing as little as 2 kilograms (4.4 pounds). This marks the first time a second-generation integrase strand transfer inhibitor (INSTI) has been cleared for patients starting from birth.[1][2][5]

The clinical stakes for this demographic are absolute. Without early diagnosis and effective antiretroviral therapy, HIV progresses aggressively in neonates. Data cited during the FDA approval process shows that approximately 50% of untreated infants born with HIV will die by their second birthday, underscoring the urgent need for immediate intervention.[2][5]

The approval rests on data from the NIH-funded IMPAACT 2023 trial, which enrolled 48 newborns who were exposed to HIV-1 and weighed at least 2 kg. These infants received the dispersible tablet formulation of dolutegravir from birth for up to six weeks, alongside standard-of-care antiretrovirals used to prevent mother-to-child transmission.[1][3][6]

Researchers followed the cohort for 16 weeks, utilizing pharmacokinetic modeling to confirm that the drug reached therapeutic concentrations in term neonates. The safety profile mirrored what has been established in older children and adults, with no new safety signals or unexpected adverse events emerging in the newborn group.[2][3][6]

Dolutegravir works by blocking HIV integrase, the enzyme the virus uses to insert its viral DNA into the human host cell. As a second-generation INSTI, it carries a significantly higher barrier to viral resistance than earlier drugs—a crucial feature for infants who are facing a lifetime of daily antiretroviral therapy.[5]

Previously, Tivicay PD was restricted to children who were at least four weeks old and weighed a minimum of 3 kg. The expanded indication bridges a critical four-week vulnerability window, allowing pediatricians to initiate a highly potent regimen immediately after birth rather than waiting a month while the virus replicates.[1][6]

The formulation itself is designed for pediatric realities. Tivicay PD comes as a dispersible tablet for oral suspension, allowing it to be administered to infants who cannot swallow pills. However, clinicians must be careful not to interchange the standard tablets with the dispersible tablets on a milligram-per-milligram basis.[1][6]

While the approval represents a major clinical milestone, parents and providers should understand that the drug is not a universal solution for all neonatal HIV cases. It is explicitly indicated for term infants, meaning premature babies or those under the 2 kg threshold must still rely on legacy antiretroviral protocols until further pharmacokinetic data is gathered to ensure safety in those fragile populations.[4][7]